The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin.
Helperby Therapeutics Ltd (Helperby) has presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens.
Click here to read the full paper